ZA200902454B - Use of serum amyloid a gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents - Google Patents
Use of serum amyloid a gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agentsInfo
- Publication number
- ZA200902454B ZA200902454B ZA200902454A ZA200902454A ZA200902454B ZA 200902454 B ZA200902454 B ZA 200902454B ZA 200902454 A ZA200902454 A ZA 200902454A ZA 200902454 A ZA200902454 A ZA 200902454A ZA 200902454 B ZA200902454 B ZA 200902454B
- Authority
- ZA
- South Africa
- Prior art keywords
- glaucoma
- diagnosis
- gene
- identification
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/615,454 US7662389B2 (en) | 2003-12-17 | 2006-12-22 | Use of serum amyloid A gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200902454B true ZA200902454B (en) | 2010-07-28 |
Family
ID=39205179
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200902454A ZA200902454B (en) | 2006-12-22 | 2007-12-17 | Use of serum amyloid a gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents |
Country Status (18)
Country | Link |
---|---|
US (2) | US7662389B2 (es) |
EP (2) | EP2120926A1 (es) |
JP (1) | JP2010513563A (es) |
KR (1) | KR20090101889A (es) |
CN (1) | CN101563081A (es) |
AR (1) | AR064499A1 (es) |
AU (1) | AU2007337059A1 (es) |
BR (1) | BRPI0720847A2 (es) |
CA (1) | CA2669916A1 (es) |
CL (1) | CL2007003800A1 (es) |
ES (1) | ES2424123T3 (es) |
MX (1) | MX2009004402A (es) |
RU (2) | RU2461378C2 (es) |
SA (1) | SA07280713B1 (es) |
TW (1) | TW200833842A (es) |
UY (1) | UY30837A1 (es) |
WO (1) | WO2008079783A1 (es) |
ZA (1) | ZA200902454B (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100113481A1 (en) * | 2003-12-17 | 2010-05-06 | Alcon Research, Ltd. | Use of serum amyloid a gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents |
US7662389B2 (en) * | 2003-12-17 | 2010-02-16 | Alcon, Inc. | Use of serum amyloid A gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents |
TWI398261B (zh) * | 2003-12-17 | 2013-06-11 | Alcon Inc | 血清類澱粉a基因於診斷及治療青光眼及鑑定抗青光眼劑上之用途 |
CN101921799B (zh) * | 2010-01-18 | 2014-02-26 | 德赛诊断系统(上海)有限公司 | 马血清淀粉样蛋白a1制备方法及表达载体和基因工程菌 |
WO2011127616A1 (en) * | 2010-04-13 | 2011-10-20 | M-Lab Ag | Diagnostic methods for glaucoma |
CN103160575B (zh) * | 2011-12-15 | 2014-10-01 | 王荣芳 | SAA1β/β纯合子基因型在肝硬化预后诊断及肝硬化诊断中的应用 |
WO2013173789A2 (en) | 2012-05-17 | 2013-11-21 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide compositions |
DK2855500T3 (da) * | 2012-05-24 | 2020-09-14 | Ionis Pharmaceuticals Inc | Fremgangsmåder og sammensætninger til modulering af apolipoprotein (A)-ekspression |
WO2015072580A1 (ja) * | 2013-11-14 | 2015-05-21 | 学校法人同志社 | 細胞増殖促進または細胞障害抑制による角膜内皮治療薬 |
WO2017110093A1 (ja) | 2015-12-24 | 2017-06-29 | 学校法人同志社 | TGF-βシグナルに起因する障害を治療または予防するための医薬およびその応用 |
EA201992004A1 (ru) * | 2017-04-04 | 2020-02-20 | Кинарус Аг | Способы предотвращения или лечения офтальмологических заболеваний |
CN112410419A (zh) * | 2020-12-17 | 2021-02-26 | 德赛诊断系统(上海)有限公司 | 基于淬灭探针的血清淀粉样蛋白a1基因型的检测方法和试剂盒 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8311018D0 (en) | 1983-04-22 | 1983-05-25 | Amersham Int Plc | Detecting mutations in dna |
US4998617A (en) | 1986-09-15 | 1991-03-12 | Laura Lupton Inc | Facial cosmetic liquid make up kit |
US5459039A (en) | 1989-05-12 | 1995-10-17 | Duke University | Methods for mapping genetic mutations |
FR2650840B1 (fr) | 1989-08-11 | 1991-11-29 | Bertin & Cie | Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications |
US6004744A (en) | 1991-03-05 | 1999-12-21 | Molecular Tool, Inc. | Method for determining nucleotide identity through extension of immobilized primer |
WO1994016101A2 (en) | 1993-01-07 | 1994-07-21 | Koester Hubert | Dna sequencing by mass spectrometry |
US5593826A (en) | 1993-03-22 | 1997-01-14 | Perkin-Elmer Corporation, Applied Biosystems, Inc. | Enzymatic ligation of 3'amino-substituted oligonucleotides |
US5545628A (en) | 1995-01-10 | 1996-08-13 | Galephar P.R. Inc. | Pharmaceutical composition containing fenofibrate |
US20020102581A1 (en) | 1999-02-19 | 2002-08-01 | Hageman Gregory S. | Diagnostics and therapeutics for ocular disorders |
ATE323482T1 (de) * | 1999-07-02 | 2006-05-15 | Stuart A Lipton | Verwendung von p38 mapk inhibitoren in der behandlung von augenkrankheiten |
US6103756A (en) * | 1999-08-11 | 2000-08-15 | Vitacost Inc. | Ocular orally ingested composition for prevention and treatment of individuals |
US6433018B1 (en) | 2001-08-31 | 2002-08-13 | The Research Foundation Of State University Of New York | Method for reducing hypertrophy and ischemia |
US20100113481A1 (en) * | 2003-12-17 | 2010-05-06 | Alcon Research, Ltd. | Use of serum amyloid a gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents |
US7662389B2 (en) * | 2003-12-17 | 2010-02-16 | Alcon, Inc. | Use of serum amyloid A gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents |
TWI398261B (zh) * | 2003-12-17 | 2013-06-11 | Alcon Inc | 血清類澱粉a基因於診斷及治療青光眼及鑑定抗青光眼劑上之用途 |
-
2006
- 2006-12-22 US US11/615,454 patent/US7662389B2/en not_active Expired - Fee Related
-
2007
- 2007-12-17 CN CNA2007800466103A patent/CN101563081A/zh active Pending
- 2007-12-17 EP EP07865765A patent/EP2120926A1/en not_active Withdrawn
- 2007-12-17 ES ES11009733T patent/ES2424123T3/es active Active
- 2007-12-17 MX MX2009004402A patent/MX2009004402A/es active IP Right Grant
- 2007-12-17 EP EP11009733.4A patent/EP2428210B1/en not_active Not-in-force
- 2007-12-17 ZA ZA200902454A patent/ZA200902454B/xx unknown
- 2007-12-17 KR KR1020097010390A patent/KR20090101889A/ko not_active Application Discontinuation
- 2007-12-17 AU AU2007337059A patent/AU2007337059A1/en not_active Abandoned
- 2007-12-17 WO PCT/US2007/087797 patent/WO2008079783A1/en active Application Filing
- 2007-12-17 CA CA002669916A patent/CA2669916A1/en not_active Abandoned
- 2007-12-17 BR BRPI0720847-2A patent/BRPI0720847A2/pt not_active IP Right Cessation
- 2007-12-17 JP JP2009543115A patent/JP2010513563A/ja active Pending
- 2007-12-17 TW TW096148197A patent/TW200833842A/zh unknown
- 2007-12-17 RU RU2009128245/15A patent/RU2461378C2/ru not_active IP Right Cessation
- 2007-12-21 CL CL200703800A patent/CL2007003800A1/es unknown
- 2007-12-21 UY UY30837A patent/UY30837A1/es not_active Application Discontinuation
- 2007-12-21 AR ARP070105864A patent/AR064499A1/es unknown
- 2007-12-29 SA SA07280713A patent/SA07280713B1/ar unknown
-
2009
- 2009-11-13 US US12/617,795 patent/US20100063052A1/en not_active Abandoned
-
2012
- 2012-06-06 RU RU2012123516/15A patent/RU2012123516A/ru unknown
Also Published As
Publication number | Publication date |
---|---|
US7662389B2 (en) | 2010-02-16 |
RU2009128245A (ru) | 2011-01-27 |
US20070208043A1 (en) | 2007-09-06 |
SA07280713B1 (ar) | 2012-01-24 |
WO2008079783A1 (en) | 2008-07-03 |
TW200833842A (en) | 2008-08-16 |
CL2007003800A1 (es) | 2008-08-22 |
MX2009004402A (es) | 2009-05-11 |
AU2007337059A1 (en) | 2008-07-03 |
JP2010513563A (ja) | 2010-04-30 |
RU2012123516A (ru) | 2013-12-20 |
EP2428210B1 (en) | 2013-07-10 |
US20100063052A1 (en) | 2010-03-11 |
CA2669916A1 (en) | 2008-07-03 |
KR20090101889A (ko) | 2009-09-29 |
UY30837A1 (es) | 2008-07-03 |
EP2120926A1 (en) | 2009-11-25 |
AR064499A1 (es) | 2009-04-08 |
CN101563081A (zh) | 2009-10-21 |
ES2424123T3 (es) | 2013-09-27 |
RU2461378C2 (ru) | 2012-09-20 |
BRPI0720847A2 (pt) | 2014-03-04 |
EP2428210A1 (en) | 2012-03-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200902454B (en) | Use of serum amyloid a gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents | |
HK1210274A1 (en) | Methods and ophthalmic devices used in the treatment of ocular allergies | |
EP1694192A4 (en) | USE OF SERUM AMYLOID A GENE IN DIAGNOSIS AND TREATMENT OF GLUCKOM AND IDENTIFICATION OF ANTI-GLUCKOMIC AGENTS | |
IL199045A0 (en) | Antagonist anti-notch3 antibodies and their use in the prevention and treatment of notch3-related diseases | |
IL217159A0 (en) | Device and methods for integrated continuous manufacturing of biological molecules | |
IL197240A0 (en) | Wnt antagonists and their use in the diagnosis and treatment of wnt-mediated disorders | |
EP1838284A4 (en) | ULTRASOUND THERAPEUTIC AGENT DELIVERY NANOPARTICLES AND METHODS THEREOF | |
EP1786311A4 (en) | VOLUMETRIC POINT BROADING FUNCTION FOR EYE DIAGNOSIS AND TREATMENT | |
GB0817279D0 (en) | A releasable mask and disposable body thereof | |
PL383268A1 (pl) | Kompozycje oftalmiczne i sposoby leczenia oczu | |
IL179227A0 (en) | Methods and reagents for the treatment of immunoinflammatory disorders | |
EP1858533A4 (en) | USE OF AMNIOTIC LIQUID (AF) IN THE TREATMENT OF EYE DISEASES AND INJURIES | |
PL2287195T3 (pl) | Przeciwciała pan-kir2dl receptora nk i ich zastosowanie w diagnostyce i terapii | |
IL193800A0 (en) | Endothelin and endothelin receptor agonists in the treatment of metabolic diseases | |
EP1874800A4 (en) | DIAGNOSTIC AND THERAPEUTIC AGENTS | |
PL1905443T3 (pl) | Ciecz zawierająca trehalozę do zastosowania przy zapobieganiu przywieraniu tkanek | |
IL186510A0 (en) | Variant forms of urate oxidase and use thereof | |
PL2276485T3 (pl) | Stosowanie epotilonu D w leczeniu chorób związanych z Tau, w tym choroby Alzheimera | |
EP2001503A4 (en) | DIAGNOSIS AND TREATMENT OF MORBUS ALZHEIMER | |
EP2091566A4 (en) | COMBINATION THERAPIES AGAINST ALZHEIMER DISEASE AND SIMILAR ILLNESSES | |
EP1758605A4 (en) | PROUROGUANYLIN AS THERAPEUTIC AND DIAGNOSTIC AGENTS | |
EP2323680A4 (en) | PROTEINS FOR USE IN THE DIAGNOSIS AND TREATMENT OF INFECTIONS AND DISEASES | |
EP2094281A4 (en) | USE OF LIPID CONJUGATES IN THE TREATMENT OF DISEASES OR OCULAR DISORDERS | |
EP1825005A4 (en) | MER-DIAGNOSTIC AND -THERAPEUTIC AGENTS | |
EP2089420A4 (en) | PROTEINS FOR USE IN THE DIAGNOSIS AND TREATMENT OF INFECTIONS AND DISEASES |